GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Zimmer Biomet Holdings Inc (XSWX:ZBH) » Definitions » 3-Year EPS without NRI Growth Rate

Zimmer Biomet Holdings (XSWX:ZBH) 3-Year EPS without NRI Growth Rate : 10.00% (As of Dec. 2023)


View and export this data going back to 2003. Start your Free Trial

What is Zimmer Biomet Holdings 3-Year EPS without NRI Growth Rate?

Zimmer Biomet Holdings's EPS without NRI for the three months ended in Dec. 2023 was CHF1.90.

During the past 12 months, Zimmer Biomet Holdings's average EPS without NRI Growth Rate was 145.10% per year. During the past 3 years, the average EPS without NRI Growth Rate was 10.00% per year. During the past 5 years, the average EPS without NRI Growth Rate was -7.20% per year. During the past 10 years, the average EPS without NRI Growth Rate was -2.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Zimmer Biomet Holdings was 46.70% per year. The lowest was -26.90% per year. And the median was 8.60% per year.


Competitive Comparison of Zimmer Biomet Holdings's 3-Year EPS without NRI Growth Rate

For the Medical Devices subindustry, Zimmer Biomet Holdings's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zimmer Biomet Holdings's 3-Year EPS without NRI Growth Rate Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Zimmer Biomet Holdings's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Zimmer Biomet Holdings's 3-Year EPS without NRI Growth Rate falls into.



Zimmer Biomet Holdings 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.


Zimmer Biomet Holdings  (XSWX:ZBH) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.


Zimmer Biomet Holdings 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Zimmer Biomet Holdings's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Zimmer Biomet Holdings (XSWX:ZBH) Business Description

Traded in Other Exchanges
Address
345 East Main Street, Warsaw, IN, USA, 46580
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two thirds of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.